Contact Information:
Alexandr Golejashvili
Tbilisi, Georgia
Biochimpharm owns the large privatized production facility for phage tablets and some other products in the main building. The company was only formed in 2000 and is licensed to produce dysentary tablets and several other products, but has been able to make only limited use to date of the large facilities. The area is in relatively good shape physically, with large if old fermenters and excellent filtration devices and machines that could make 100,000 tablets per hour. They have just been awarded an ISTC grant in combination with the Eliava Institute's Liana Gachechiladze to focus on Serratia as well as Pseudomonas. They are negotiating the final work plan and beginning some refurbishing
Contact Information:
Rosemonde Mandeville
Montreal, Canada
Phone: (514) 496-1488
Fax: (514) 496-1521
Email: email@biophage.com
…………………………………………………………………………………………………………………………………………………………
Biopharm Pharmaceuticals
Contact Information:
Lado Gulisashvili and Lela Kalandarishvili
Tbilisi, Georgia
Email: biopharm@got.ge
Biopharm obtained most of original big main production plant of the Eliava Institute after privatization, and has enhanced its capacity with much good equipment obtained from bankrupt companies, including in Moscow. They make vitamins, various biomedical reagents, probiotics, and currently also about 20 liters a month of phage products, including pills. They use primarily the phages that were being produced before privatization, with some research focused on methods of delivery that can be patented, such as new capsule formulations
………………………………………………………………………………………………………………………………………………………………
Contact Information:
Richard Carlton, M.D.
150 Main Street
Port Washington, NY 11050
Phone: (516) 883-6883
Fax: (516) 883-6903
Email: carltonebi@erols.com
……………………………………………………………………………
Contact Information:
J. Ramachandran
3279 Emerson
Palo Alto, CA 94306
Phone: 650-856 9118
Fax: 650-856 9642
Email: jram@gangagen.com
Gangagen Life Sciences Inc:
Dr. Kishore Murthy,
Chief Scientific Officer
1740, Woodroffe Ave,
Building 400, Suite # 2
Ottawa, Ontario, K2G3R8
Email: kmurthy@gangagen.com
Gangagen Biotechnologies Ltd:
Dr. Goda Krishna
#5 AC, 705 II Block, Hennur Road
Banaswadi Layout, Bangalore 560043
Phone: +91-80-5448138/5448146
Fax: 91-80-5447996
Email: godakrishna@gangagen.com
Contact Information:
HEXAL Gentech ForschungsGmbH
Industriestr. 25, 83607
Holzkirchen, Germany
Email: info@greinerbioone.com
Immunopreparat Research Productive Association
Contact Information:
Novorossiiskaya 105, 450024
Ufa Bashkortostan, Russian Federation
Immunopreparat is a large pharmaceutical company in Russia, which is located in the city of Ufa (approximately 60 miles west of the Ural Mountains). The company’s subsidiary, Biophag, currently manufactures at least two complex phage
preparations (“Bacteriophagum” and “Piobacteriaphagum”) targeting various bacterial pathogens
………………………………………………………………………………………………………………………………………………………………………………
Contact Information:
Contact: Torrey Brown
The Warehouse at Camden Yards
323 W. Camden Street, Suite 675
Baltimore, Maryland 21201
Phone: (410) 659-7330
Fax: (410) 625-2323
EMail: info@Intralytix.com
………………………………………………………………………………………………………………………………………………………………………………..
Micropeace
Contact Information:
Contact: Dr. Ipek Kurtboke
LPO Box 2093
Hawthorn, Melbourne, Victoria 3122
Australia
Phone: +61 (03) 9813 5660
Fax: +61 (03) 9813 5660
Email: micropeace@hotmail.com
Developing new compounds for future use against drug-resistant bacteria and/or for chemical modifications for field applications by screening for new metabolites and evaluating the potential of less known or new bacteria taxa.. Bacteriophage are being used as natural indicators of the presence of rare taxa in a selected test substrate, to determine the relatedness of the isolated taxa and to deselect unwanted taxa on isolation plates in the process of target specific selective isolations. Micropeace provides consultancy to biotechnology companies and research institutes interested in detection of rare or novel actinomycetes and other bacteria on ways to use phages as effective tools in this search.
…………………………………………………………………………………………………………………………………………………………………………………..
Contact Information:
Dr J. Nick Housby, PhD – Chief Executive Officer and Director
j.n.housby@novolytics.co.uk
Professor Nick H Mann, PhD – Chief Scientific Officer and Director
n.mann@novolytics.co.uk
Warwick Ventures
University House
Kirby Corner Road
Coventry, UK CV4 8UW
Contact Information:
Asher Wilf
4, Pekeris St., Rabin Science Park
Rehovot 76702, Israel
Cell: +972-52-446782
Phone: 972-8-947-1837
Fax: +972 8-947-1845
Email: asher@phage-biotech.com or info@phage-biotech.com
Special Phage Services Pty Ltd
Contact Information
Dr Anthony M. Smithyman, Managing Director
7/27 Dale Street
Brookvale
NSW 2100 Australia
Smithyman@cellabs.com.au
phone: +61 2 9905 0133
fax: +61 2 9905 6426
Special Phage Services Pty Ltd. was established in October 2002 as a specialist phage therapy services company by immunologist Dr. Anthony Smithyman. SPS is a start-up company formed in response to the growing concern of antibiotic resistance and the need for alternative solutions to antibiotic use. SPS has access to phage production know-how as well as a phage library of over 3,000 strains through an exclusive license with a well known Georgian-based company. SPS plans to develop and commercialise in Australasia and Asia a range of proprietary, tailored phage therapeutics (SmartPhageTM) for use in human and animal health, food and environmental markets.
Contact Information
7170 Frederick Banting
2nd Floor
St. Laurent, QC H4S 2A1
phone: (514) 332-1008
fax: (514) 332-6033
Targanta is developing small-molecule antibacterial agents aiming at the disruption of the DNA replication and transcription machinery through the targets of bacteriophages (“phages”), viruses that attack bacteria. This approach effectively mimics strategies devised through four billion years of evolutionary pressure with regards to the selection of druggable bacterial targets, in contrast to current drug discovery efforts, which often focus on comparative functional bacterial genomics. The Company has been able to identify the molecular interactions enabling phages to hamper bacterial sustainability, and thereby has validated an innovative process for identifying novel drug targets and a new class of proprietary antibacterial molecules. Targanta's approach circumvents the demonstrated limitations of sequencing bacterial genomes as a way to identify novel antibacterial targets and new classes of antibacterials. The Company is in the process of converting this unique expertise in terms of target validation into novel antibacterial drugs
